Comparison of Four Infusion Methods for Lutathera Peptide Radionuclide Receptor Therapy

182 null Introduction: null null Peptide radionuclide receptor therapy (PRRT) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) commenced at our institution in June 2018. The treatment course requires the infusion of Lutathera with concurrent renoprotective amino acid infusion over 4 hours, with a total of 4 cycles given at eight-week intervals. To provide an effective and safe method for the infusion of Lutathera...